Literature DB >> 3164184

Phosphorylation, anti-HIV activity and cytotoxicity of 3'-fluorothymidine.

E Matthes1, C Lehmann, D Scholz, H A Rosenthal, P Langen.   

Abstract

3'-fluorothymidine (FddThd) is well phosphorylated to the 5'-triphosphate in various relevant cell-lines. This results in fairly stable levels of this compound without accumulation of the 5'-monophosphate to the extent described for 3'-azidothymidine (AzT). The di- and triphosphate of FddThd seems unable to influence the ribonucleotide reductase in permeable cells. FddThd protects 50% of the MT-4 cells against the cytopathic effect of HIV at 3 nM, but reduces the number of uninfected viable cells to 50% at 1.1 microM. All other tested human cell-lines displayed a far less antiproliferative sensitivity to FddThd, comparable with that of AzT.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164184     DOI: 10.1016/s0006-291x(88)81170-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3'-deoxy-3'-fluorothymidine in comparison to 3'-azido-3'-deoxythymidine.

Authors:  I W Blau; E Elstner; M Waechter; R Ihle; M von Janta-Lipinski; P Langen
Journal:  Blut       Date:  1989-11

2.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

3.  Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs.

Authors:  E Matthes; K Reimer; M von Janta-Lipinski; H Meisel; C Lehmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus.

Authors:  M M Mansuri; M J Hitchcock; R A Buroker; C L Bregman; I Ghazzouli; J V Desiderio; J E Starrett; R Z Sterzycki; J C Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 5.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides.

Authors:  E Matthes; P Langen; M von Janta-Lipinski; H Will; H C Schröder; H Merz; B E Weiler; W E Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

8.  The anti-human immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells.

Authors:  R Sundseth; S S Joyner; J T Moore; R E Dornsife; I K Dev
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; John M Hoffman; Janet F Eary; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

10.  The evolving role of nuclear molecular imaging in cancer.

Authors:  Ka Kurdziel; G Ravizzini; By Croft; Jl Tatum; Pl Choyke; H Kobayashi
Journal:  Expert Opin Med Diagn       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.